Enterprise Value
17.2M
Cash
58.04M
Avg Qtr Burn
-8.778M
Short % of Float
2.49%
Insider Ownership
2.68%
Institutional Own.
58.25%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Uproleselan (GMI-1271) Details Acute myeloid leukemia, Cancer | Phase 3 Data readout | |
Uproleselan (GMI-1271) +/- Daunorubicin and Cytarabine Details Acute myeloid leukemia | Phase 2/3 Data readout | |
Uproleselan (GMI-1271) +/- myeloablative, busulfan-based, pre-transplant conditioning Details Blood cancer, Acute myeloid leukemia | Phase 1/2 Data readout | |
Uproleselan (GMI-1271) +/-fludarabine & cytarabine Details Blood cancer, Acute myeloid leukemia | Phase 1/2 Data readout | |
GMI-1687 Details Sickle cell disease | Phase 1a Data readout | |
Rivipansel (GMI-1070) Details SCD (Sickle Cell Disease) | Failed Discontinued | |
GMI-1359 Details Breast cancer | Failed Discontinued |